Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and safety of gadoquatrane in pediatric subjects undergoing contrast-enhanced MRI
2022-501883-17-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of gadoquatrane, sponsored by Bayer. Primary endpoints: Area under the curve (AUC) of gadoquatrane after single administration, Plasma clearance normalized to body weight (CL/BW) of gadoquatrane after single administration and 2 more. Started Oct 2023; status: completed.
02
Drugs
gadoquatrane
Beyond the preview
Go deeper on 2022-501883-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501883-17-00.